Defect Correction for ADT™ Booster

HPS Pharmacies wish to give notice that Seqirus, in consultation with the Therapeutic Goods Administration (TGA), has issued a product defect correction for ADT™ Booster as follows:

ADT™ Booster
Diphtheria and Tetanus Vaccine
ARTG 130919

The only batch affected by this notice is DT403A (expiry 31/01/2026)

This defect alert was initiated as a small number of syringes in batch DT403A are missing the batch number and expiry details on the syringe label. These details are still present on the box containing the syringe and the syringe is still identifiable as ADT™ Booster. Therefore, the health risk to patients is considered low.

Seqirus advises staff to inspect stock and identify any syringes with a labelling defect. If a defect is found, the product carton should be referred to for batch and expiry details. The vaccine may still be administered, but the syringes must not be removed from the carton until they are to be used.

Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Seqirus on 1800 642 865 or your pharmacist at HPS Pharmacies.

Download PDF